Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC26A3 | P40879 | 6/20 | 0.74 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.65 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.65 |
| ▸ | ACHE | P22303 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | MAOB | P27338 | 4/20 | 0.59 |
| ▸ | MIF | P14174 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24045270 | 0.88 | SLC26A3 (0.74) | SLC26A3CTDSP1RCE1ACHEKDM4E | |
| SCHEMBL26687589 | 0.82 | SLC26A3 (1.00) | SLC26A3CTDSP1MEN1KMT2A | |
| SCHEMBL30154899 | 0.82 | SLC26A3 (1.00) | SLC26A3CTDSP1MEN1KMT2A | |
| SCHEMBL18095309 | 0.79 | CA12 (0.69) | CTDSP1KDM4EALDH1A1HPGDMEN1 | |
| SCHEMBL20554014 | 0.77 | CA12 (0.83) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL10681805 | 0.77 | KDM4E (0.64) | CTDSP1KDM4EALDH1A1HPGDMEN1 | |
| SCHEMBL7432074 | 0.75 | ACHE (1.00) | ACHEMAOBMAOA | |
| SCHEMBL26434315 | 0.75 | ALDH1A1 (1.00) | CTDSP1ACHEKDM4EALDH1A1HPGD | |
| SCHEMBL5617624 | 0.75 | MAOB (1.00) | ACHEMAOBMAOA | |
| SCHEMBL26434307 | 0.75 | ALDH1A1 (0.84) | KDM4EALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591304-B2 | SLC26A3 inhibitors and use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210363123-A1 | SLC26A3 INHIBITORS AND USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363123-A1 | SLC26A3 INHIBITORS AND USE THEREOF | SLC26A3, SLC10A2, SLC10A6 | SLC26A3 1/4885CTDSP1 3224/4885RCE1 4524/4885 |
| US-11591304-B2 | SLC26A3 inhibitors and use thereof | SLC26A3, SLC10A2, SLC10A6 | SLC26A3 1/4885CTDSP1 3224/4885RCE1 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.